Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tmunity Closes $100 Million Funding for T Cell Therapies; Ping An Participates

publication date: Jan 23, 2018

Tmunity Therapeutics, a Philadelphia biopharma developing next-gen immuno-oncology drugs, closed a $100 million Series A round that included Ping An as its first-named investor. Using technology developed at the University of Pennsylvania, Tmunity is developing a broad-based portfolio of T cell therapies for oncology, infectious diseases and autoimmune diseases. Tmunity’s portfolio produces engineered T cells that activate or suppress immunity. Its approaches include T cell receptors, regulatory T cells, Crispr-Cas9 gene editing, allogeneic T cells and bionic T cells, as well as CAR-T programs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China